The state of Alabama currently has 4 active clinical trials seeking participants for Amyotrophic Lateral Sclerosis research studies. These trials are conducted in various cities, including Birmingham, Mobile, Huntsville and Anniston.
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: University of Alabama Birmingham, Birmingham, Alabama
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Yogic Breathing Exercise for People With Amyotrophic Lateral Sclerosis
Recruiting
The aim of this study is to understand how well a 6-week virtual yogic breathing exercise program (YBEP) will improve breathing, speech, and emotional well-being in people with amyotrophic lateral sclerosis (ALS).
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
11/07/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Amyotrophic Lateral Sclerosis
AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis
Recruiting
The UAB Institute for Arts In Medicine (AIM) is currently implementing an expressive emotional writing pilot project for adults with paralysis caused by neurological conditions such as traumatic head or spinal cord injury.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/27/2023
Locations: 354 School of Health Professions Building, Birmingham, Alabama
Conditions: Spinal Cord Injuries, Multiple Sclerosis, Transverse Myelitis, Amyotrophic Lateral Sclerosis
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
Recruiting
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Gender:
All
Ages:
Between 18 years and 81 years
Trial Updated:
04/14/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Amyotrophic Lateral Sclerosis